UTHR

United Therapeutics Corporation

$591.20

−$1.64 (0.28%)Oct 27 close

Health CareS&P 400 Compare Technicals

1M 3M 6M 1Y 2Y

UTHRSPY

Wall St. Highest PT $728.00 (+23.1%) Wall St. Avg PT $661.29 (+11.9%)

Underwater Drawdown %Max DD -20.9%Current -0.9%

Relative Strength vs SPY+26.9% vs SPYOutperforming

+$37.32 (6.74%)

+$115.75 (24.35%)

+$67.57 (12.90%)

+$22.09 (3.88%)

YTD

+$103.95 (21.33%)

+$170.16 (40.41%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar

Wall Street analyst consensus

Buy

15 analysts · mean score 1.87

1 = Strong Buy · 5 = Sell

Strong Buy320%

Buy853%

Hold320%

Underperform17%

Sell00%

Wall Street consensus

Analyst price targets

Current price$591.20

Average target$661.29

+$70.09 (+11.9%) upsideaverage target vs current price

CurrentAverageMedian

Low$368.00

Median$700.00

High$728.00

12-month Wall Street target range

Recent analyst rating changes · 30

Reiterated

2026-10-22 · RBC Capital reiterated Outperform on UTHR

Reiterated

2026-10-19 · Leerink Partners reiterated Outperform on UTHR

Reiterated

2026-10-08 · RBC Capital reiterated Outperform on UTHR

Reiterated

2026-10-07 · Morgan Stanley reiterated Equal-Weight on UTHR

Upgrade

2026-10-01 · BTIG upgraded UTHR from Neutral to Buy

Initiated

2026-09-24 · Goldman Sachs started covering UTHR at Sell

All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$25.2B

P/E (last 12 months)20.3

P/E (next 12 months, estimated)17.5

52-week range$409.07 – $609.35

Revenue growth (latest quarter vs a year ago)-1.9%

Dividend yieldNo dividend

Analyst consensusBuy (14)

Average analyst price target$661.29 (+12%)

What they do

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer. It also markets and sells Unituxin (dinutuximab) injection.

Healthcare · Drug Manufacturers - Specialty & Generic

Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum

53rd percentile in sector

C+

12-1 return: +21.7%
Percentile within its GICS sector across the S&P 1500.

Growth

8th percentile in sector

Revenue growth (YoY): -1.9%
Percentile within its GICS sector across the S&P 1500.

Value

63rd percentile in sector

B-

Forward E/P: 6.3% · EBITDA/EV: 7.4%
Percentile within its GICS sector across the S&P 1500.

Profitability

84th percentile in sector

A-

Profit margin: +41.6% · Return on equity: +19.3%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth

Outside this model's universe or screens

Momentum Top 15

Outside this model's universe or screens

Momentum Blend

Not in the current book

New Highs Growth

ranked 64 of 589 · 12-month momentum 20.3%

SURVYR. Barbell Momentum & T-Bill Shield

Outside this model's universe or screens

SURVYR. Physical AI Grid & Power

Outside this model's universe or screens

SURVYR. Long Book

Not in the current book

Earnings & events

UTHR earningsNext report in 8 days

Next report · quarter Sep 2026

Wed Nov 4, 2026Before the open

EPS consensus$6.36 range $4.68–$7.11

Revenue consensus$781.5M 13 analysts

Last 4 quarters · EPS vs estimate

Aug 5, 2026$7.27est $6.86+6.0%Above estimates

May 6, 2026$5.82est $6.86−15.1%Below estimates

Feb 25, 2026$7.70est $6.76+14.0%Above estimates

Oct 29, 2025$7.16est $6.96+2.9%Above estimates

In line = within 1% of the estimate.

EstimateActual (beat)Actual (miss)

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$783.3M	-1.9%
2026-03-31	$781.5M	–
2025-12-31	$790.2M	–
2025-09-30	$799.5M	–
2025-06-30	$798.6M	–

News & catalysts

More news

2 healthcare stocks to keep an eye on and 1 that underwhelm

StockStory · Oct 23

United Therapeutics (UTHR) files 8-K: other event

SEC 8-K · Oct 22

Rating changes

Reiterated

2026-10-22 · RBC Capital reiterated Outperform on UTHR

Reiterated

2026-10-19 · Leerink Partners reiterated Outperform on UTHR

Reiterated

2026-10-08 · RBC Capital reiterated Outperform on UTHR

Reiterated

2026-10-07 · Morgan Stanley reiterated Equal-Weight on UTHR

Upgrade

2026-10-01 · BTIG upgraded UTHR from Neutral to Buy

Initiated

2026-09-24 · Goldman Sachs started covering UTHR at Sell

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades

Rothblatt Martine A